Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Tuesday the launch of Baclofen Oral Suspension, a generic alternative to Fleqsuvy.
Baclofen Oral Suspension is a treatment for spasticity from multiple sclerosis or spinal cord injuries and other spinal cord diseases. Fleqsuvy is marketed by Azurity Pharmaceuticals Inc.
Total US annual sales for Baclofen Oral Suspension amount to approximately USD39m, according to IQVIA data.
ANI Pharmaceuticals launches generic Motegrity tablets
Hikma Pharmaceuticals USA receives FDA approval for diabetes drug
Full Circles Therapeutics advances non-viral gene editing innovation
Induction Healthcare secures national video solution contract in Ireland
Safecor Health acquires Viatris' US unit-dose packaging business
LOG Pharma Primary Packaging opens new clean room
American Regent launches 30 mL Epinephrine Injection, USP in US
EpiVax and CUBRC receive USD2m contract from US FDA
Gilead expands global access to lenacapavir for HIV prevention